At Tillotts, our collaborations with healthcare professionals and healthcare organisations are an essential part of advancing patient care. These interactions—ranging from scientific exchange and advisory activities to educational initiatives—support a better understanding of diseases and contribute to the responsible development and use of our medicines.
The support provided by Tillotts to healthcare professionals (HCPs), healthcare organisations (HCOs), and patient organisations (POs) reflects our commitment to high standards of ethical conduct and integrity. Such collaborations represent an important and legitimate investment in research, education, and the continuous improvement of healthcare outcomes for patients.
Although Tillotts is not a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), we recognise the importance of transparency in our interactions with the healthcare community. We therefore disclose transfers of value in line with internationally transparency principles and applicable national codes and applicable laws, contributing to greater openness and accountability.
Why We Disclose Transfers of Value
We believe that the disclosure of transfers of value serves important legitimate purposes, including:
Transparency helps reinforce the foundation for continued collaboration, ensuring that these relationships remain focused on delivering value to patients and society.
Legal Basis for Disclosure
Further details on how personal data is processed, as well as on the scope and methodology of disclosures, are available in the corresponding Methodological Note.
Access to Disclosures
Our disclosures provide an overview of the transfers of value made by Tillotts to healthcare professionals and healthcare organisations and are published on an annual basis.